Skip to main content
GDTC
NASDAQ Life Sciences

Director & 10% Owner Buys $128K in Open Market Amidst Financial Concerns

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.14
Mkt Cap
$13.489M
52W Low
$0.68
52W High
$3.68
52W Position info
68% above low
Off High info
69% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

GDTC sits 68% above its 52-week low of $0.68 on light trading volume (0.2× avg).

Summary

A Director and 10% owner of CytoMed Therapeutics purchased $128,778 in open market shares, signaling confidence despite recent financial distress.


Key Events · Ownership and Investor Activity · GDTC

  • Director & 10% Owner Buys Shares

    Choo Chee Kong, a Director and 10% owner, purchased 112,000 shares of CytoMed Therapeutics in the open market for a total of $128,778 at $1.15 per share on May 13, 2026.

  • Insider Confidence Amidst Financial Distress

    This significant insider purchase provides a positive signal of confidence, coming after the company disclosed a going concern warning and widened net losses in recent filings.

  • Substantial Investment

    The $128,778 investment is notable for a company of this market capitalization, representing nearly 1% of the company's total value.


Analysis · GDTC · Life Sciences

This open market purchase by a Director and 10% owner is a strong signal of insider confidence, especially significant given the company's recent financial challenges, including a going concern warning and widened net losses. The investment of $128,778 represents a substantial commitment relative to the company's market valuation.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GDTC was trading at $1.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.5M. The 52-week trading range was $0.68 to $3.68. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GDTC - Latest Insights

GDTC
Oct 13, 2026, 6:14 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.8114
Real-time Price: $0.781 info
Change: -$0.0304 (-4%) info
Market Cap: $9.813M info
GDTC
Oct 09, 2026, 7:43 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.8114
Real-time Price: $0.781 info
Change: -$0.0304 (-4%) info
Market Cap: $9.813M info
GDTC
Sep 30, 2026, 9:15 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.9197
Real-time Price: $0.781 info
Change: -$0.1387 (-15%) info
Market Cap: $9.813M info
GDTC
Jul 24, 2026, 12:33 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $0.990
Real-time Price: $0.781 info
Change: -$0.209 (-21%) info
Market Cap: $9.813M info
GDTC
Jun 23, 2026, 12:14 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.996
Real-time Price: $0.781 info
Change: -$0.215 (-22%) info
Market Cap: $9.813M info